Tazemetostat - Epizyme

Drug Profile

Tazemetostat - Epizyme

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; National Cancer Institute (USA)
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Soft tissue sarcoma; Diffuse large B cell lymphoma; Rhabdoid tumour; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Non-small cell lung cancer
  • Phase I B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 02 Aug 2018 A partial hold on enrolment in clinical trials for Solid tumours and Haematological malignancies in Germany prior to August 2018
  • 02 Aug 2018 Epizyme announces intention to submit NDA application for Follicular lymphoma in the first half of 2019
  • 02 Aug 2018 Interim efficacy data from a phase II trial in Synovial sarcoma released in Epizyme second quarter report
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top